Early CMV-replication after allogeneic stem cell transplantation is associated with a reduced relapse risk in lymphoma.
A preventive effect of early human cytomegalovirus (HCMV) replication was evaluated in 136 non-Hodgkin lymphoma (NHL) patients with mature B-cell NHLs (n = 94), and mature T- and NK-cell NHLs (n = 42) after allogeneic stem cell transplantation (alloSCT). Most study-patients (85%) had received at least 2 cycles of chemotherapy and 60% had also received an autograft prior to alloSCT. First detection of CMV-replication by HCMV antigenemia/viremia was found at a median of day +33 after alloSCT. The cumulative incidence of relapse at 5 years after alloSCT was 38% (95% confidence interval [95%CI]: 26-49) in 82 patients without compared to 22% (95%CI: 8-37) in 54 patients with HCMV antigenemia/viremia (p = .013). A decreased relapse risk of HCMV replication was confirmed by multivariate analysis for HCMV antigenemia/viremia (Hazard ratio [HR]: 0.29, 95%CI: 0.11-0.76, p < .014). This report demonstrated a possible improvement of relapse incidence after replicative HCMV infection in patients with NHL after alloSCT.
a Department of Bone Marrow Transplantation , West German Cancer Center, University Hospital Essen, University of Duisburg-Essen , Essen , Germany.
Michael
M
Koldehoff
b Institute of Virology, University Hospital Essen, University of Duisburg-Essen , Essen , Germany.
Stefan R
SR
Ross
c Department of Hematology , West German Cancer Center, University Hospital Essen, University of Duisburg-Essen , Essen , Germany.
Ulrich
U
Dührsen
a Department of Bone Marrow Transplantation , West German Cancer Center, University Hospital Essen, University of Duisburg-Essen , Essen , Germany.
Dietrich W
DW
Beelen
a Department of Bone Marrow Transplantation , West German Cancer Center, University Hospital Essen, University of Duisburg-Essen , Essen , Germany.|d Department of Oncology and Hematology , HELIOS Schwerin , Schwerin , Germany.
Ahmet H
AH
Elmaagacli
D000293:Adolescent; D000328:Adult; D000368:Aged; D003587:Cytomegalovirus / Q000502:physiology*; D003586:Cytomegalovirus Infections / Q000175:diagnosis / Q000209:etiology* / Q000517:prevention & control; D005260:Female; D006086:Graft vs Host Disease / Q000209:etiology / Q000517:prevention & control; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D008223:Lymphoma / Q000150:complications* / Q000401:mortality / Q000473:pathology* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D011379:Prognosis; D016016:Proportional Hazards Models; D019233:Retreatment; D019172:Transplantation Conditioning / Q000009:adverse effects; D014184:Transplantation, Homologous; D014766:Viremia; D014779:Virus Replication; D055815:Young Adult
HCMV; alloSCT; lymphoma